Performance study of a 360° CZT camera for monitoring 177Lu-PSMA treatment
-
Published:2023-09-22
Issue:1
Volume:10
Page:
-
ISSN:2197-7364
-
Container-title:EJNMMI Physics
-
language:en
-
Short-container-title:EJNMMI Phys
Author:
Vergnaud LaureORCID, Badel Jean-Noël, Giraudet Anne-Laure, Kryza David, Mognetti Thomas, Baudier Thomas, Rida Hanan, Dieudonné Arnaud, Sarrut David
Abstract
Abstract
Background
The aim of this study was to investigate the quantification performance of a 360° CZT camera for 177Lu-based treatment monitoring.
Methods
Three phantoms with known 177Lu activity concentrations were acquired: (1) a uniform cylindrical phantom for calibration, (2) a NEMA IEC body phantom for analysis of different-sized spheres to optimise quantification parameters and (3) a phantom containing two large vials simulating organs at risk for tests. Four sets of reconstruction parameters were tested: (1) Scatter, (2) Scatter and Point Spread Function Recovery (PSFR), (3) PSFR only and (4) Penalised likelihood option and Scatter, varying the number of updates (iterations × subsets) with CT-based attenuation correction only. For each, activity concentration (ARC) and contrast recovery coefficients (CRC) were estimated as well as root mean square. Visualisation and quantification parameters were applied to reconstructed patient image data.
Results
Optimised quantification parameters were determined to be: CT-based attenuation correction, scatter correction, 12 iterations, 8 subsets and no filter. ARC, CRC and RMS results were dependant on the methodology used for calculations. Two different reconstruction parameters were recommended for visualisation and for quantification. 3D whole-body SPECT images were acquired and reconstructed for 177Lu-PSMA patients in 2–3 times faster than the time taken for a conventional gamma camera.
Conclusion
Quantification of whole-body 3D images of patients treated with 177Lu-PSMA is feasible and an optimised set of parameters has been determined. This camera greatly reduces procedure time for whole-body SPECT.
Publisher
Springer Science and Business Media LLC
Subject
Radiology, Nuclear Medicine and imaging,Instrumentation,Biomedical Engineering,Radiation
Reference49 articles.
1. Miyahira AK, Soule HR. The history of prostate-specific membrane antigen as a theranostic target in prostate cancer: the cornerstone role of the prostate cancer foundation. J Nucl Med. 2022;63(3):331–8. https://doi.org/10.2967/jnumed.121.262997.Accessed2022-12-21. 2. Ahmadzadehfar H, Eppard E, Kürpig S, Fimmers R, Schlenkhoff CD, Gärtner F, Rogenhofer S, Essler M. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016;7:12477. 3. Kratochwil C, Giesel FL, Stefanova M, Benešová M, Bronzel M, Afshar-Oromieh A, Mier W, Eder M, Kopka K, Haberkorn U. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617. J Nucl Med. 2016;57(8):1170–6. https://doi.org/10.2967/jnumed.115.171397.Accessed2022-12-15. 4. Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, Francis RJ, Gedye C, Rutherford NK, Weickhardt A, Scott AM, Lee S-T, Kwan EM, Azad AA, Ramdave S, Redfern AD, Macdonald W, Guminski A, Hsiao E, Chua W, Lin P, Zhang AY, McJannett MM, Stockler MR, Violet JA, Williams SG, Martin AJ, Davis ID, Azad AA, Chua W, Davis ID, Dhiantravan N, Emmett L, Ford K, Hofman MS, Francis RJ, Gedye C, Goh JC, Guminski A, Hsiao E, Iravani A, Joshua AM, Kirkwood ID, Langford A, Lawrence N, Lee S-T, Lin P, Martin AJ, McDonald W, McJannett MM, Ng S, Pattison DA, Ramdave S, Rana N, Redfern AD, Rutherford NK, Sandhu S, Scott AM, Stockler MR, Subramaniam S, Tan TH, Violet JA, Weickhardt A, Williams SG, Yip S, Zhang AY. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797–804. https://doi.org/10.1016/S0140-6736(21)00237-3.Accessed2022-12-15. 5. Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Sch M, Baum RP, Kulkarni HR, Schmidt M, Drzezga A, Bartenstein P, Pfestroff A, Luster M, Mottaghy FM, Ruf J, Meyer PT, Heuschkel M, Eveslage M, Fendler WP, Krause BJ. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58:85–90.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|